This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site.
Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
Thank you for visiting the Astellas Pharma Inc. Website.
You will enter external sites beyond here. (This link opens in a new window)
- Sponsors Tomorrow’s Hero in February and March 2018. : Tomorrow’s Hero showcases young innovators who are transforming the world for a brighter future -
Tokyo, February 16, 2018 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) launched “CNN Tomorrow’s Hero” as a part of its global corporate brand campaign which in collaboration with CNN. The new multiplatfrom campaign...
- Acquisition enables Astellas to fully utilize proprietary technology to produce pluripotent stem cells that have the potential to lower immunological rejection in numerous therapeutic areas -
Tokyo, February 13, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Universal Cells, Inc. (CEO: Claudia Mitchell, “Universal Cells”) today announced that Aste...
Tokyo, February 8, 2018 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the results of two Phase 3 trials (RAJ3 and RAJ4 trials) on Peficitinib hydrobromide (generic name; development code: ASP015K, “Peficitinib”), an oral JAK inhibitor developed by Astellas, in rheumatoid arthritis patients with an inadequate response to existing therapy, demonstra...